Results 181 to 190 of about 65,986 (255)

Bioinformatic Identification and Experimental Validation of a Prognostic Transcriptional Signature Derived from Asparagine Metabolism-Related Genes in Breast Cancer. [PDF]

Biology (Basel)
Liu T, Zhang G, Li J, Yan X, Ma M.
europepmc   +1 more source

Enhancing diagnostic precision for BI‐RADS 4a breast nodules: A multimodal AI model integrating ultrasound radiomics, hemodynamic signatures, and clinical profiles

Journal of Applied Clinical Medical Physics, Volume 27, Issue 10, October 2026.
Abstract Background Breast Imaging Reporting and Data System (BI‐RADS) 4a nodules represent a diagnostic dilemma, with a malignancy rate ranging from 2% to 10%. The majority of these nodules prove benign after biopsy, leading to unnecessary invasive procedures, patient anxiety, and healthcare costs.
Jun Yang, Longman Long, Guang Li, Jian Zeng, Caixiao Peng, Jingting Yan   +5 more
wiley   +1 more source

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA. [PDF]

Cancers (Basel)
Uccello M, Boussios S, Maï C, Worton H, Bazire A, de Buhren B.   +5 more
europepmc   +1 more source

Multi‐regional Organoid Biobank Reveals FAK‐ACSL1‐Driven Doxorubicin‐Resistance and Predictive Biomarkers in Breast Cancer

Advanced Science, Volume 13, Issue 55, 5 October 2026.
This study established a high‐quality organoid biobank derived from 68 tumor sites across 50 Chinese patients, elucidated the drug sensitivity‐based molecular subtyping in breast cancer, and revealed a novel mechanism of drug resistance mediated by the FAK‐ACSL1 pathway.
Hao Xu, Zhijun Qin, Jiapeng Yang, Baoyuan Zhang, Manqing Cao, Peng Wang, Zaiqi Wang, Jinghui Cheng, Lei Wang, Hong Liu, Hui Yang   +10 more
wiley   +1 more source

MicroRNA Signatures of Fulvestrant-Treated Luminal Breast Cancer Cells: Identification of Therapeutic Targets Regulated by <i>miR-374b-5p</i>. [PDF]

Int J Mol Sci
Nagata A, Tomioka Y, Yasudome R, Toda H, Tokunaga T, Nagata Y, Kato M, Shinden Y, Nakajo A, Seki N.   +9 more
europepmc   +1 more source

SWE-BRCA

, 2016
SWE-BRCA
core  

Pan‐Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Multiple public databases, including TCGA, GEO, and TARGET, were utilized to comprehensively analyze pyridoxal phosphatase (PDXP) expression profiles across 34 cancer types. We further explored the associations of PDXP expression with clinicopathological features, tumor immune microenvironment, genomic heterogeneity, functional signaling ...
Yingjian Hu, Xinzhu Zeng, Wei Cao, Jianhao Jiao, Yuan Zhao, Jun Wang   +5 more
wiley   +1 more source

Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer. [PDF]

PLoS One
Deng O, Nepomuceno TDC, Fang B, Welsh EA, Izumi V, Martin RH, George EM, Koomen JM, Monteiro AN, Rix U.   +9 more
europepmc   +1 more source

CCNE1: A Cell Cycle Regulator That Influences Tumor Progression

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACTCyclin E1 (CCNE1), a pivotal member of the cyclin family, governs the G1/S phase transition of the cell cycle by binding to and activating cyclin‐dependent kinase 2 (CDK2), thereby initiating DNA replication and driving S‐phase entry. In a broad spectrum of human malignancies—including breast, ovarian, gastric, and non‐small cell lung cancers ...
Liang Yan, Siyi Liu, Yanling Li, Qian He, Chen Long, Ning Tang, Yanhong Zhou   +6 more
wiley   +1 more source

PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies. [PDF]

Front Cell Dev Biol
Ouhajjou A, Mazouji O, Nejjari C, Incitti R, Mansour H.   +4 more
europepmc   +1 more source